Marijuana Advocacy Groups Meet State Officials After Reclassification
State cannabis reclassification impact is reshaping patient access and regulatory frameworks. Advocacy groups meet with officials to influence policy changes. These developments affect clinical practice and patient care.
DOJ Schedule III cannabis order creates uncertainty for D.C.’s medical self-certification program
The DOJ Schedule III cannabis order creates regulatory uncertainty for D.C.’s medical self-certification program. This federal scheduling change may disrupt patient access to medical cannabis. Clinicians and patients must understand the implications of…
White House and GOP Lawmaker Push 2026 Hemp Legislation Updates
2026 hemp legislation updates are shaping the future of hemp-derived THC products. These regulatory changes impact clinical practice and patient access nationwide. Understanding these updates is crucial for navigating the evolving hemp THC legal…
DEA Reschedules FDA-Approved Marijuana Products and State-Licensed Medical Cannabis
The DEA reschedules marijuana products impacting FDA-approved and state-licensed medical cannabis. This creates distinct regulatory pathways for cannabis medicines. Patient access and insurance coverage may be influenced by these changes.
‘Less red tape:’ Public and political perception of cannabis continues to change – YouTube
Public perception cannabis is evolving rapidly, affecting patient access to medical cannabis programs. Political attitudes are shifting toward harm reduction and regulation updates. These changes impact clinicians and healthcare providers directly.
Trump Urges Congress to Address Federal Hemp Product Ban
The federal hemp product ban is creating uncertainty for patient access and clinical care. Trump calls on Congress to fix the law imposing this forthcoming ban. Clinicians must monitor regulatory changes closely to ensure treatment continuity.
Cotton: Change to marijuana drug classification ‘a step in the wrong direction’
The cannabis drug classification debate highlights significant clinical and regulatory challenges. Opposition to DEA reclassification affects research access and patient care pathways. Clinicians must navigate this evolving policy landscape carefully.
Sudden Cannabis Reclassification Leaves Maryland Industry, Regulators Confused
Maryland cannabis reclassification has caused confusion among industry regulators and patients. This sudden change affects medical cannabis patient access and regulatory clarity. Clinicians and patients are urged to seek guidance during this transition.
How 2026 Cannabis Tax Relief Could Help Cannabis Businesses
2026 cannabis tax relief cannabis businesses may ease financial pressures by reducing tax burdens. This change could improve patient access by lowering product costs. Cannabis companies might reinvest savings into quality and research.
Characterizing Public Comments on Cannabis Rescheduling via Regulations.gov
This study analyzes cannabis rescheduling public comments submitted to Regulations.gov in 2024. Over 42,000 comments reveal diverse stakeholder perspectives on DEA's proposed Schedule III change. Understanding these comments helps clinicians anticipate…